(UroToday.com) Stimulator of interferon genes (STING) recognizes nucleotide backbones to provoke type I interferon production to accelerate immune responses. In tumor therapy, STING agonist has been used as local treatment in many cancer types. The investigators developed intravesical STING therapy empowered by super-enhanced drug delivery system with urease-nanomotor attached nanoparticles.
Urease-nanomotor was attached to nanocomplex composed of polydopamine (PDA). The STING agonist was incorporated into the nanomotor attached PDA. Murine bladder cancer model was established by instilling MB-49 bladder cancer cells through urethra. STING agonist incorporated nanocomplex was also delivered through bladder instillation. The mobility of urease-nanomotor PDA was empowered in urine in motion analysis and its penetration was highly enhanced in ex vivo experiments using rat bladder.
Furthermore, dendritic cell activation was increased by STING agonist incorporated into nanomotor attached PDA compared with free STING agonist. In murine bladder cancer model, STING agonist incorporated into urease nanomotor-PDA provided powerful antitumor effect by nearly eliminating established bladder tumors. Moreover cytotoxic T cell infiltration was also significantly increased by urease nanomotor empowered STING agonist.
Presented by: Seung-hwan Jeong, MD, Seoul National University Hospital
Written by: Roger Li, Urologic Oncologist, Moffitt Cancer Center, during the International Bladder Cancer Network Annual Meeting, September 28-October 1, 2022, Barcelona, Spain